The Company has created and continues to develop a rich pipeline of proprietary, flexible, delivery systems combined with the expertly formulated ingredients to deliver highly effective therapeutics to a precisely targeted area.
The Company's current focus is a range of dermatological applications utilising its unique formulation and delivery technologies to meet cosmetic unmet needs. This range will include the Company’s new, potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. The Company is currently focussed upon delivering this range to a commercial partner.
Originating from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford, the Company has acquired and developed a portfolio of specific cancer-targeting therapeutics, with a strategy to develop each candidate from initial acquisition/discovery to commercially valuable partnerships at the earliest opportunity in its development pathway.